Abiopharma

OpenWorld 與 Figure Technology Solutions 擬推進 OpenWorld 證券在 Figure 的 OPEN 網絡上的代幣化

OpenWorld 与 Figure Technology Solutions 拟推进 OpenWorld 证券在 Figure 的 OPEN 网络上的代币化

Silicom to Participate in 21st Annual Needham Technology, Media, & Consumer Conference

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

UFP Packaging Expands National Pallet Manufacturing Network, Strengthening Coast-to-Coast Reach

Investis Notification - Smith+Nephew PLC

Johnson & Johnson - Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson - Johnson & Johnson study showsTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohns disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Elkhart Clinic Joins American Oncology Network, Becomes Elkhart Hematology and Oncology